author-photo

Steffen Walter

University of Tübingen

78

Papers

2974

Citations

Citation Trend

Filter By

Papers (60) Sort By

Journal Conference Others

Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT127: Phase I adoptive cellular therapy trial with actively personalized, multi-targeted CD8+ T-cells in patients with relapsed and/or refractory solid cancers (ACTologIMA101-101)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
1155PPhase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance

2017 Immunological Reviews
Show All
- Source
- Cite
- Save
Citations (53)
Abstract 2291: On- and off target toxicity profiling for adoptive cell therapy by mass spectrometry-based immunopeptidome analysis of primary human normal tissues

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Sorafenib but not sunitinib affects the induction of immune responses

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study

2016 Cancer Immunology, Immunotherapy
Show All
- Source
- Cite
- Save
Citations (133)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

2016 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (111)
New T-cell receptors and their use in immunotherapy

2016
Show All
- Source
- Cite
- Save
Citations (0)